BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chin KL, Sarmiento ME, Alvarez-Cabrera N, Norazmi MN, Acosta A. Pulmonary non-tuberculous mycobacterial infections: current state and future management. Eur J Clin Microbiol Infect Dis 2020;39:799-826. [PMID: 31853742 DOI: 10.1007/s10096-019-03771-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Rosenbloom R, Gavrish I, Tseng AE, Seidel K, Yabaji SM, Gertje HP, Huber BR, Kramnik I, Crossland NA. Progression and Dissemination of Pulmonary Mycobacterium Avium Infection in a Susceptible Immunocompetent Mouse Model. IJMS 2022;23:5999. [DOI: 10.3390/ijms23115999] [Reference Citation Analysis]
2 Smirnova T, Ustinova V, Andreevskaya S, Larionova E, Kiseleva E, Chernousova L, Varlamov D, Sochivko D, Ergeshov A. Evaluation of a new assay for nontuberculous mycobacteria species identification in diagnostic material and cultures. Tuberculosis (Edinb) 2021;130:102124. [PMID: 34488079 DOI: 10.1016/j.tube.2021.102124] [Reference Citation Analysis]
3 Nakamura K, Nakayama H, Sasaki S, Takahashi K, Iwabuchi K. Mycobacterium avium-intracellulare complex promote release of pro-inflammatory enzymes matrix metalloproteinases by inducing neutrophil extracellular trap formation. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-09017-y] [Reference Citation Analysis]
4 Kempisty A, Augustynowicz-Kopec E, Opoka L, Szturmowicz M. Mycobacterium szulgai Lung Disease or Breast Cancer Relapse-Case Report. Antibiotics (Basel) 2020;9:E482. [PMID: 32764357 DOI: 10.3390/antibiotics9080482] [Reference Citation Analysis]
5 Villanueva-Montes MÁ, Álvarez Navascués F, Gullón Blanco JA, Rodrigo Sanz T, Medina Gallardo JF, Caminero Luna JA, García-García JM; Grupo de Trabajo del Programa Integrado de Investigación en Tuberculosis (PII-TB) de SEPAR. [Translated article] Non-Tuberculous Mycobacterial Diseases in Spain: Treatment and Evolution. Arch Bronconeumol 2022:S0300-2896(22)00293-9. [PMID: 35513946 DOI: 10.1016/j.arbres.2022.01.023] [Reference Citation Analysis]
6 Yamada H, Chikamatsu K, Aono A, Murata K, Miyazaki N, Kayama Y, Bhatt A, Fujiwara N, Maeda S, Mitarai S. Fundamental Cell Morphologies Examined With Cryo-TEM of the Species in the Novel Five Genera Robustly Correlate With New Classification in Family Mycobacteriaceae. Front Microbiol 2020;11:562395. [PMID: 33304323 DOI: 10.3389/fmicb.2020.562395] [Reference Citation Analysis]
7 Thornton CS, Mellett M, Jarand J, Barss L, Field SK, Fisher DA. The respiratory microbiome and nontuberculous mycobacteria: an emerging concern in human health. Eur Respir Rev 2021;30:200299. [PMID: 34039671 DOI: 10.1183/16000617.0299-2020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Tan Y, Deng Y, Yan X, Liu F, Tan Y, Wang Q, Bao X, Pan J, Luo X, Yu Y, Cui X, Liao G, Ke C, Xu P, Li X, Zhang C, Yao X, Xu Y, Li T, Su B, Chen Z, Ma R, Jiang Y, Ma X, Bi D, Ma J, Yang H, Li X, Tang L, Yu Y, Wang Y, Song H, Liu H, Wu M, Yang Y, Xue Z, Li L, Li Q, Pang Y. Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study. J Infect 2021;83:46-53. [PMID: 34048821 DOI: 10.1016/j.jinf.2021.05.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Grzegorzewicz A, Paściak M. The key factors contributing to the risk, diagnosis and treatment of non-tuberculous mycobacterial opportunistic infections. Postępy Higieny i Medycyny Doświadczalnej 2021;75:696-710. [DOI: 10.2478/ahem-2021-0050] [Reference Citation Analysis]
10 Nakayama H, Oshima E, Hotta T, Hanafusa K, Nakamura K, Yokoyama N, Ogawa H, Takamori K, Iwabuchi K. Identification of anti-lipoarabinomannan antibodies against mannan core and their effects on phagocytosis of mycobacteria by human neutrophils. Tuberculosis (Edinb) 2022;132:102165. [PMID: 35045376 DOI: 10.1016/j.tube.2022.102165] [Reference Citation Analysis]
11 Pinheiro AC, Nogueira TCM, da Costa CF, Lourenço C, Low JN, Wardell JL, Wardell SMSV, de Souza MVN. A study of antituberculosis activities and crystal structures of ( E )-2-[2-(arylidene)hydrazinyl]pyrimidine and ( E )- N1 -(arylidene)pyrimidine-2-carbohydrazide derivatives. Zeitschrift für Naturforschung B 2020;75:1011-28. [DOI: 10.1515/znb-2020-0108] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ishida E, Corrigan DT, Malonis RJ, Hofmann D, Chen T, Amin AG, Chatterjee D, Joe M, Lowary TL, Lai JR, Achkar JM. Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes. Commun Biol 2021;4:1181. [PMID: 34642445 DOI: 10.1038/s42003-021-02714-w] [Reference Citation Analysis]
13 Chavas TEJ, Su FY, Srinivasan S, Roy D, Lee B, Lovelace-Macon L, Rerolle GF, Limqueco E, Skerrett SJ, Ratner DM, West TE, Stayton PS. A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis. J Control Release 2021;330:284-92. [PMID: 33221351 DOI: 10.1016/j.jconrel.2020.11.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]